Seres Therapeutics, Inc. (MCRB)
NASDAQ: MCRB · Real-Time Price · USD
7.88
+0.82 (11.54%)
At close: May 12, 2025, 4:00 PM
8.09
+0.21 (2.73%)
After-hours: May 12, 2025, 7:59 PM EDT
MCRB's stock price has decreased by -61.4% in the past year and price targets may not have had time to catch up.
Seres Therapeutics Analyst Ratings
Total Analysts
5
Consensus Rating
Hold
Price Target
$73.67
Upside
+835.49%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy → Hold Downgrades $1.25 → $6 | Strong Buy → Hold | Downgrades | $1.25 → $6 | -23.81% | May 8, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +217.46% | Mar 20, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Sell Maintains $20 → $15 | Strong Sell | Maintains | $20 → $15 | +90.48% | Mar 14, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $200 | Strong Buy | Maintains | $200 | +2,439.68% | Nov 14, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +217.46% | Nov 13, 2024 |
| JP Morgan | JP Morgan | Hold → Sell Downgrades n/a | Hold → Sell | Downgrades | n/a | n/a | Oct 24, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $200 | Strong Buy | Maintains | $200 | +2,439.68% | Sep 13, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $200 | Strong Buy | Maintains | $200 | +2,439.68% | Aug 14, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +217.46% | Aug 14, 2024 |
| Oppenheimer | Oppenheimer | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Jun 7, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $300 → $200 | Strong Buy | Maintains | $300 → $200 | +2,439.68% | Jun 7, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $100 → $80 | Buy | Maintains | $100 → $80 | +915.87% | May 9, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $160 → $120 | Strong Buy | Maintains | $160 → $120 | +1,423.81% | May 8, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $180 → $100 | Buy | Maintains | $180 → $100 | +1,169.84% | Mar 6, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $200 → $160 | Strong Buy | Maintains | $200 → $160 | +1,931.75% | Mar 6, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $200 → $180 | Buy | Maintains | $200 → $180 | +2,185.71% | Jan 16, 2024 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 10 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.